Genomic at market outperform by JMP

JMP Securities analyst Charles C. Duncan reiterated Genomic Health, Inc. at market outperform after the company announced the online publication of the chemotherapy benefit study in the Journal of Clinical Oncology. JMP believes the peer-reviewed publication of these data could encourage reimbursement policy decisions by third-party payors. The company also announced a large-scale National Cancer Institute trial of about 10,000 patients will take place using Oncotype DX to study the effects of adjuvant chemotherapy in patients with mid-range risk of recurrence. Shares of the Redwood City, Calif., biotechnology company were up 36 cents, or 3.52%, at $10.59 on volume of 84,458 shares versus the three-month running average of 107,210 shares. (Nasdaq: GHDX)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.